TABLE 1

Baseline patient characteristics

CPEErlotinib monotherapyAll
Patients111122
Age, years60 (58–64)67 (62–68)64 (59–68)
Males5 (45)5 (45)10 (45)
Performance score
 08 (73)7 (64)15 (68)
 13 (27)4 (36)7 (32)
Smoking
 Never-smoker6 (55)2 (18)8 (36)
 Former smoker5 (45)5 (45)10 (45)
 Current smoker0 (0)4 (36)4 (18)
 Pack-years14 (9–15)14 (6–19)14 (7–18)
Stage IV11 (100)11 (100)22 (100)
Nonsquamous11 (100)11 (100)22 (100)
Type of EGFR mutation
 Exon 19 deletion7 (64)7 (64)14 (64)
 L858R2 (18)3 (27)5 (23)
 Other2 (18)1 (9)3 (13)

Data are presented as n, median (interquartile range) or n (%). CPE: cisplatin-pemetrexed-erlotinib; EGFR: epidermal growth factor receptor.